Company intelligence / Profile preview
Aridis Pharmaceuticals, Inc.
San Jose, California, United Statesaridispharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aridis has multiple clinical-stage programs with AR-301 and AR-320 in Phase 3 trials for VAP, and AR-501 having completed Phase 2a trials for cystic fibrosis. The company recently executed an Asset Acquisition Terms Agreement for AR-501 worth $6,500,000 and is working with an investment firm to fund the completion of AR-301's second Phase 3 study.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Monoclonal antibodies (mAbs)Small moleculesAnti-infectivesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
National Institute of Allergy and Infectious DiseasesHarvard UniversityUndisclosed pharmaceutical company (AR-501 acquisition)
Beyond the preview
Go deeper on Aridis Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aridis Pharmaceuticals, Inc..